DAVIS JOHN C. JR 4
4 · Magenta Therapeutics, Inc. · Filed Jun 27, 2018
Insider Transaction Report
Form 4
DAVIS JOHN C. JR
Chief Medical Officer
Transactions
- Conversion
Common Stock
2018-06-25+8,304→ 8,304 total - Conversion
Series C Preferred Stock
2018-06-25−21,459→ 0 total→ Common Stock (8,304 underlying)
Footnotes (1)
- [F1]The Series C Preferred Stock converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Series C Preferred Stock had no expiration date.